Ajanta FDA Tuesday, April 7, 2026 0.00 Neutral

FDA Approves IVERMECTIN — Ajanta Pharma USA Inc.

# FDA Approves Generic Ivermectin ANDA from Ajanta Pharma USA Inc. Ajanta Pharma USA Inc. has received FDA approval for its generic ivermectin oral formulation (ANDA218509), expanding the competitive landscape in the antiparasitic market and potentially increasing price pressure on existing ivermectin suppliers. The approval is expected to enhance market accessibility and drive down treatment costs for patients requiring ivermectin therapy.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day